Consider an additional dose at least 28 days after the initial 2-dose primary series for people with moderate to severe immune compromise.

Requires VAERS reporting.

Years with underlying medical conditions or aged 18-64 years at increased risk for SARS-CoV-2 exposure and transmission because of occupational or institutional settings.

Also a booster dose at least 6 months after primary series completion may be considered (based on individual benefits and risks) for people aged 18-49.

All currently authorized or approved COVID-19 vaccines

<table>
<thead>
<tr>
<th>Vaccine type</th>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
<th>Janssen</th>
</tr>
</thead>
</table>
| Age groups   | 12 through 15 years of age (authorized) 
              ≥ 16 years (approved COMIRNATY) | ≥18 years | ≥18 years |
| Dose         | 30 µg           | 100 µg  | 5×10¹⁰ viral particles |
| Dose volume  | 0.3 ml          | 0.5 ml  | 0.5 ml  |
| Number of doses in primary series | 2* | 2* | 1 |
| Interval between doses  | 3 weeks (21 days) | 1 month (28 days) | N/A |

Interchangeability of vaccines

- Vaccines are not interchangeable. However, in exceptional situations, such as a contraindication to a second dose of mRNA vaccine or when a previous dose product cannot be determined or is not available, interchangeability may be allowed (https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html).

Interval between COVID-19 and other (non-COVID-19) vaccines

- COVID-19 vaccine and other vaccines may be administered on the same day, as well as any interval without respect to timing. When deciding whether to administer COVID-19 vaccine and other vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable diseases (e.g., during an outbreak), and the reactogenicity profile of the vaccines.

Persons with prior or current COVID-19

- COVID-19 vaccines can be given safely to people with prior SARS-CoV-2 infection.
- Defer vaccination until person has recovered from the acute illness and criteria have been met for them to discontinue isolation (https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html).

Women aged <50 years

- Can receive any FDA-authorized or approved vaccine but should be informed of risk of thrombosis with thrombocytopenia syndrome (TTS) after receipt of Janssen (Johnson & Johnson) COVID-19 vaccine and the availability of other COVID-19 vaccine options.

Persons who received monoclonal antibodies or convalescent plasma for COVID-19 treatment

- Defer vaccination for at least 90 days.

Persons with a known SARS-CoV-2 exposure

- Persons in community or outpatient setting should defer vaccination until quarantine period has ended (https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html).
- Residents or patients in congregate settings may be vaccinated if they do not have symptoms consistent with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html).

History of heparin-induced thrombocytopenia (HIT)

- If within 90 days of illness, offer an mRNA vaccine, after 90 days vaccinate with any FDA-authorized or approved COVID-19 vaccine.

Persons with underlying conditions

- May receive COVID-19 vaccine.

Persons with moderate to severe immune compromise

- Can receive any FDA-authorized or approved COVID-19 vaccine
  - 1 dose Janssen COVID-19 Vaccine; currently no recommendation for an additional dose, or
  - 2 doses of an mRNA COVID-19 vaccine; consider an additional dose at least 28 days after completion of the primary 2-dose series

Persons with a history of myocarditis or pericarditis

- If myocarditis or pericarditis occurred after a dose of an mRNA COVID-19 vaccine, should defer receiving a subsequent dose
- A subsequent dose can be considered in certain circumstances including personal risk of severe COVID-19 and level of community transmission.
- If a history of myocarditis or pericarditis unrelated to an mRNA COVID-19 vaccination, may receive COVID-19 vaccine after the episode has completely resolved.

Persons with a history of Guillain-Barré Syndrome

- Can receive any FDA-authorized or approved COVID-19 vaccine, however, discuss the availability of mRNA vaccines to offer protection against COVID-19.

Pregnant or breastfeeding people or people trying to get pregnant

- Are recommended to receive a COVID-19 vaccine, inform of risk of TTS after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other options.

Adolescents

- Adolescents aged 12-17 are ONLY eligible for Pfizer-BioNTech COVID-19 Vaccine
- Adolescents aged 18 years and older are eligible for all COVID-19 vaccines.

Persons vaccinated outside the United States

- Received all recommended doses of an FDA-authorized or approved COVID-19 vaccine, do not need additional doses
- Received a non-FDA-authorized or approved vaccine
  - If vaccine is listed for emergency use by the World Health Organization (WHO) and received all recommended doses, do not need any additional doses with an FDA-authorized or approved vaccine
  - If vaccine is listed for emergency use by WHO, but has not received all recommended doses, may be offered a complete FDA-authorized or approved series
- If vaccine is not listed for emergency use by WHO, may be offered a complete FDA-authorized or approved COVID-19 vaccine series

Contraindications

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine
- Immediate (within 4 hours of exposure) allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine

Precaution

- Immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies (excluding subcutaneous allergens for allergies, i.e., "allergy shots")

Post-vaccination observation periods

- 30 minutes: persons with a precaution to vaccination (i.e., history of an immediate allergic reaction of any severity to a vaccine or injectable therapy) and persons with a history of anaphylaxis due to any cause
- 15 minutes: all other persons

SARS-CoV-2 antibody testing

- Antibody testing not recommended for vaccine decision-making or to assess immunity following vaccination.